Hills Bank & Trust Co Acquires Shares of 2,379 Harrow, Inc. (NASDAQ:HROW)

Hills Bank & Trust Co acquired a new stake in shares of Harrow, Inc. (NASDAQ:HROW) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,379 shares of the company’s stock, valued at approximately $107,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Rice Hall James & Associates LLC lifted its position in Harrow by 23.1% in the 3rd quarter. Rice Hall James & Associates LLC now owns 314,881 shares of the company’s stock valued at $14,157,000 after acquiring an additional 59,019 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of Harrow by 64.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,825 shares of the company’s stock valued at $307,000 after buying an additional 2,668 shares during the last quarter. Semanteon Capital Management LP bought a new stake in Harrow during the third quarter worth $686,000. Mirae Asset Global Investments Co. Ltd. raised its position in Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after buying an additional 227 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in Harrow during the 3rd quarter valued at $8,572,000. 72.76% of the stock is owned by institutional investors.

Harrow Price Performance

Shares of NASDAQ:HROW opened at $45.64 on Friday. Harrow, Inc. has a fifty-two week low of $7.60 and a fifty-two week high of $59.23. The company’s 50-day moving average is $46.45 and its 200 day moving average is $29.70. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.43 and a current ratio of 2.60. The company has a market capitalization of $1.62 billion, a P/E ratio of -48.04 and a beta of 0.76.

Harrow (NASDAQ:HROW) last released its earnings results on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.12. Harrow had a negative net margin of 21.78% and a negative return on equity of 40.59%. The firm had revenue of $48.94 million during the quarter, compared to the consensus estimate of $42.78 million. On average, equities research analysts forecast that Harrow, Inc. will post 0.09 earnings per share for the current year.

Wall Street Analyst Weigh In

HROW has been the subject of several analyst reports. B. Riley reiterated a “buy” rating and issued a $50.00 target price on shares of Harrow in a report on Thursday, August 29th. Craig Hallum increased their price objective on shares of Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, October 4th. Finally, Lake Street Capital boosted their target price on Harrow from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, October 4th.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.